Our proprietary TCR-T cell therapy platform is supported by robust research, in collaboration with renowned laboratories, in the areas of autologous & allogeneic T cells and gene editing technologies.
August 16, 2017
|
Press Release
2017
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
August 7, 2017
Breakthrough immunotherapy for Chronic Hepatitis B virus infection
January 25, 2017
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
November 2, 2016
Events
2016
Dr. Antonio Bertoletti speaks at the World Life Science Conference 2016
August 19, 2016
Scientific Director, Dr. Sarene Koh, speaks at the 1st Transmed-VN Conference
May 26, 2016
Dr. Antonio Bertoletti presents Lion TCR T-cell therapy at the International Society for Cellular Therapy Conference 2016
